- Home
- RAPT vs VSTM Comparison
RAPT vs VSTM Comparison
Compare RAPT & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RAPT | VSTM |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 470.7M |
| IPO Year | 2019 | 2011 |
Fundamental Metrics
Financial Performance| Metric | RAPT | VSTM |
|---|---|---|
| Price | $58.00 | $5.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $56.22 | $14.50 |
| AVG Volume (30 Days) | ★ 4.6M | 1.4M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.87 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | $208.96 |
| Revenue Next Year | N/A | $269.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 285.21 |
| 52 Week Low | $0.71 | $4.01 |
| 52 Week High | $58.02 | $11.25 |
Technical Indicators
Market Signals| Indicator | RAPT | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 78.57 | 42.20 |
| Support Level | $32.00 | $5.58 |
| Resistance Level | N/A | $6.91 |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | -0.79 | 0.04 |
| Stochastic Oscillator | 90.91 | 31.74 |
Price Performance
Historical ComparisonAbout RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.